Fighting cancer with vaccinia virus: Teaching new tricks to an old dog

被引:85
作者
Shen, YQ [1 ]
Nemunaitis, J [1 ]
机构
[1] Mary Crowley Med Res Ctr, Dallas, TX 75201 USA
关键词
D O I
10.1016/j.ymthe.2004.10.015
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Vaccinia virus has played a huge part in human beings' victory over smallpox. With smallpox being eradicated and large-scale vaccination stopped worldwide, vaccinia has assumed a new role in our fight against another serious threat to human health: cancer. Recent advances in molecular biology, virology, immunology, and cancer genetics have led to the design of novel cancer therapeutics based on vaccinia virus backbones. With the ability to infect efficiently a wide range of host cells, a genome that can accommodate large DNA inserts and express multiple genes, high immunogenicity, and cytoplasmic replication without the possibility of chromosomal integration, vaccinia virus has become the platform of many exploratory approaches to treat cancer. Vaccinia virus has been used as (1) a delivery vehicle for anti-cancer transgenes, (2) a vaccine carrier for tumor-associated antigens and immunoregulatory molecules in cancer immunotherapy, and (3) an oncolytic agent that selectively replicates in and lyses cancer cells.
引用
收藏
页码:180 / 195
页数:16
相关论文
共 228 条
[91]   Vaccinia virus utilizes microtubules for movement to the cell surface [J].
Hollinshead, M ;
Rodger, G ;
Van Eijl, H ;
Law, M ;
Hollinshead, R ;
Vaux, DJT ;
Smith, GL .
JOURNAL OF CELL BIOLOGY, 2001, 154 (02) :389-402
[92]   Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule [J].
Hörig, H ;
Lee, DS ;
Conkright, W ;
Divito, J ;
Hasson, H ;
LaMare, M ;
Rivera, A ;
Park, D ;
Tine, J ;
Guito, K ;
Tsang, KWY ;
Schlom, J ;
Kaufman, HL .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2000, 49 (09) :504-514
[93]   Prostate-specific antigen vaccines for prostate cancer [J].
Hörig, H ;
Lee, CSD ;
Kaufman, HL .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2002, 2 (04) :395-408
[94]  
Hwang C, 1999, CURR OPIN MOL THER, V1, P471
[95]   Viral vectors for dendritic cell-based immunotherapy [J].
Jenne, L ;
Schuler, G ;
Steinkasserer, A .
TRENDS IN IMMUNOLOGY, 2001, 22 (02) :102-107
[96]   REPLICATION AND COATING OF VACCINIA DNA [J].
JOKLIK, WK ;
BECKER, Y .
JOURNAL OF MOLECULAR BIOLOGY, 1964, 10 (03) :452-&
[97]   Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus - poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans [J].
Kanesa-thasan, N ;
Smucny, JJ ;
Hoke, CH ;
Marks, DH ;
Konishi, E ;
Kurane, I ;
Tang, DB ;
Vaughn, DW ;
Mason, PW ;
Shope, RE .
VACCINE, 2000, 19 (4-5) :483-491
[98]  
KARUPIAH G, 1991, J IMMUNOL, V147, P4327
[99]   Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): A trial of the Eastern Cooperative Oncology group [J].
Kaufman, HL ;
Wang, W ;
Manola, J ;
DiPaola, RS ;
Ko, YJ ;
Sweeney, C ;
Whiteside, TL ;
Schlom, J ;
Wilding, G ;
Weiner, LM .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (11) :2122-2132
[100]  
Kaufman HL, 2003, HUM GENE THER, V14, P803